|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-5-17
|
|
pubmed:abstractText |
Developing continuous systemic delivery of endostatin has been a goal of many laboratories. We have employed a method of gene therapy utilizing different viral constructs. Here, we report that a new serotype of adeno-associated viruses, which incorporates canine endostatin, provides dose-dependent transgene expression in the circulation after intramuscular injection in mice. Elevated levels of endostatin remained stable in the circulation for at least 4 months. In vitro assays determined that the protein expressed was biologically active. Antitumor activities of the above construct demonstrated a U-shape curve, where the maximum activity was observed within a certain critical concentration range. These data suggest that an optimum dose range may be required to achieve therapeutic efficacy in large animal models.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0929-1903
|
|
pubmed:author |
pubmed-author:BirsnerA EAE,
pubmed-author:ChaoSS,
pubmed-author:FolkmanJJ,
pubmed-author:GayWW,
pubmed-author:GilliesSS,
pubmed-author:JavaherianKK,
pubmed-author:MAJJ,
pubmed-author:NaspinskiJJ,
pubmed-author:SamulskiJJ,
pubmed-author:Tjin Tham SjinR MRM,
pubmed-author:ZurakowskiDD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
619-27
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16456550-Amino Acid Sequence,
pubmed-meshheading:16456550-Angiogenesis Inhibitors,
pubmed-meshheading:16456550-Animals,
pubmed-meshheading:16456550-Antibodies, Monoclonal,
pubmed-meshheading:16456550-Antineoplastic Agents,
pubmed-meshheading:16456550-Cell Line, Tumor,
pubmed-meshheading:16456550-Cell Proliferation,
pubmed-meshheading:16456550-Dependovirus,
pubmed-meshheading:16456550-Dogs,
pubmed-meshheading:16456550-Dose-Response Relationship, Drug,
pubmed-meshheading:16456550-Endostatins,
pubmed-meshheading:16456550-Gene Therapy,
pubmed-meshheading:16456550-Genetic Vectors,
pubmed-meshheading:16456550-Humans,
pubmed-meshheading:16456550-Injections, Intramuscular,
pubmed-meshheading:16456550-Male,
pubmed-meshheading:16456550-Mice,
pubmed-meshheading:16456550-Mice, SCID,
pubmed-meshheading:16456550-Molecular Sequence Data,
pubmed-meshheading:16456550-Neoplasms,
pubmed-meshheading:16456550-Pancreatic Neoplasms,
pubmed-meshheading:16456550-Sequence Alignment
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Endostatin therapy reveals a U-shaped curve for antitumor activity.
|
|
pubmed:affiliation |
Vascular Biology Program, Department of Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
